Pyxis Oncology (PYXS) Current Assets (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Current Assets data on file, last reported at $72.1 million in Q4 2025.

• On a quarterly basis, Current Assets fell 45.56% year-over-year to $72.1 million in Q4 2025; TTM through Dec 2025 was $72.1 million, a 45.56% decrease from a year earlier, with the FY2025 full-year figure at $72.1 million, down 45.56% from the prior year.
• Current Assets for Q4 2025 stood at $72.1 million, down from $83.1 million in the prior quarter.
• Over the last five years, Current Assets for PYXS reached as high as $278.7 million in Q4 2021 and fell as low as $72.1 million in Q4 2025.
• Historically, Current Assets has averaged $157.3 million across 5 years, with a median of $149.1 million in 2023.
• Across the five-year window, Current Assets jumped 3339.13% in 2021 and sank 45.56% in 2025, its largest moves.
• Year by year, Current Assets stood at $278.7 million in 2021, then slumped by 33.04% to $186.6 million in 2022, then slumped by 33.23% to $124.6 million in 2023, then increased by 6.29% to $132.4 million in 2024, then sank by 45.56% to $72.1 million in 2025.
• Per Business Quant data, the three most recent Current Assets figures were $72.1 million in Q4 2025, $83.1 million in Q3 2025, and $100.0 million in Q2 2025.